发布求助
文献互助 智能选刊 最新文献

Gastroenterology and Hepatology最新文献

筛选
英文 中文
Overview of Lean MASH and MASLD. 精益MASH和MASLD概述。
Gastroenterology and Hepatology Pub Date : 2024-12-01
Vincent Wong
{"title":"Overview of Lean MASH and MASLD.","authors":"Vincent Wong","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12","pages":"745-747"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Resmetirom or Placebo in NASH Fibrosis Patients With <5% or >5% Weight Loss and/or on Baseline GLP-1 Therapy in the MAESTRO-NASH 52-Week Serial Liver Biopsy Study. 在MAESTRO-NASH 52周系列肝活检研究中，瑞司替龙或安慰剂对体重减轻5%和/或基线GLP-1治疗的NASH纤维化患者的影响
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Effect of Resmetirom or Placebo in NASH Fibrosis Patients With <5% or >5% Weight Loss and/or on Baseline GLP-1 Therapy in the MAESTRO-NASH 52-Week Serial Liver Biopsy Study.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 11","pages":"8-9"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Once-Monthly Efimosfermin Alfa (BOS-580) in Metabolic Dysfunction-Associated Steatohepatitis With F2/F3 Fibrosis: Results From a 24-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial. 每月一次的Efimosfermin Alfa （BOS-580）治疗代谢功能障碍相关脂肪性肝炎伴F2/F3纤维化：来自一项24周、随机、双盲、安慰剂对照的2期试验的结果
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Once-Monthly Efimosfermin Alfa (BOS-580) in Metabolic Dysfunction-Associated Steatohepatitis With F2/F3 Fibrosis: Results From a 24-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 11","pages":"15-16"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corticosteroid-Free Remission Through 3 Years of Upadacitinib Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 Long-Term Extension Study U-ACTIVATE. 中度至重度活动性溃疡性结肠炎患者经3年Upadacitinib治疗无糖皮质激素缓解：来自U-ACTIVATE的3期长期扩展研究数据
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Corticosteroid-Free Remission Through 3 Years of Upadacitinib Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 Long-Term Extension Study U-ACTIVATE.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 10","pages":"10-12"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784574/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of Overweight and Obesity in Patients With Inflammatory Bowel Disease. 炎症性肠病患者超重和肥胖的管理。
Gastroenterology and Hepatology Pub Date : 2024-12-01
Mark Shneyderman, Hannah Freid, David Kohler, Jellyana Peraza, Natasha Haskey, Erin Abbott, Asher Kornbluth, Maitreyi Raman, Stephanie Gold
{"title":"Management of Overweight and Obesity in Patients With Inflammatory Bowel Disease.","authors":"Mark Shneyderman, Hannah Freid, David Kohler, Jellyana Peraza, Natasha Haskey, Erin Abbott, Asher Kornbluth, Maitreyi Raman, Stephanie Gold","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Increasing evidence has linked obesity to complications of inflammatory bowel disease (IBD); however, data are limited on the efficacy and impact of weight management strategies on the disease course. There are a strikingly limited number of interventional studies on weight management in patients with IBD, and the recent nutrition and IBD guidelines published in the United States do not mention weight management strategies. Overweight and obesity management in patients with IBD should follow a stepwise approach to assessment and treatment, including lifestyle modification, anti-obesity medications such as glucagon-like peptide-1 agonists, endobariatric procedures, and bariatric surgery (if deemed appropriate). This article reviews the management of overweight and obesity in patients with IBD, examines the efficacy of currently available interventions and their impact on the IBD course, and proposes a stepwise approach to the assessment and treatment of overweight or obesity for the IBD provider.</p>","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12","pages":"712-722"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patients With Irritable Bowel Syndrome With Constipation From the IBS in America 2024 Real-World Survey Experience Burdensome Symptoms Beyond Constipation. 2024年美国IBS患者伴便秘的肠易激综合征患者经历了便秘以外的繁重症状
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Patients With Irritable Bowel Syndrome With Constipation From the IBS in America 2024 Real-World Survey Experience Burdensome Symptoms Beyond Constipation.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 9","pages":"5-7"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corticosteroid-Sparing Effects of Treatment With Guselkumab in Patients With Moderate to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results Through Week 44. guelkumab治疗中度至重度活动性溃疡性结肠炎患者的皮质激素节约效果：类星体维持研究结果至第44周
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Corticosteroid-Sparing Effects of Treatment With Guselkumab in Patients With Moderate to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results Through Week 44.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 10","pages":"9-10"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784576/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Effect of Obeticholic Acid on Inflammatory Markers and Fibrosis Scores in POISE Incomplete Responders: A Retrospective Review of POISE, a Phase 3 Trial of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis. 奥比胆酸对POISE不完全应答者炎症标志物和纤维化评分的影响：一项回顾性评价POISE，一项用奥比胆酸治疗原发性胆管炎的3期试验。
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"The Effect of Obeticholic Acid on Inflammatory Markers and Fibrosis Scores in POISE Incomplete Responders: A Retrospective Review of POISE, a Phase 3 Trial of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 12","pages":"12"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Efficacy of Maintenance Treatment With Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results at Week 44 by Biologic/Janus Kinase Inhibitor History. guelkumab维持治疗对中度至重度活动性溃疡性结肠炎患者的疗效：类星体维持研究第44周生物/Janus激酶抑制剂史的3期结果
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"The Efficacy of Maintenance Treatment With Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results at Week 44 by Biologic/Janus Kinase Inhibitor History.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 10","pages":"5-6"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis: Pooled Interim Results for Up to 3 Years From the ASSURE Study. 开放标签塞拉德帕治疗原发性胆道胆管炎患者的长期疗效和安全性：来自ASSURE研究的3年中期汇总结果
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis: Pooled Interim Results for Up to 3 Years From the ASSURE Study.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 12","pages":"8-9"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信